NCT04771676已完成2 期
A Phase II Study of Intraperitoneal Injection of Oncolytic Viruses H101 for Patients With Refractory Malignant Ascites
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 25
- 试验地点
- 1
- 主要终点
- Time to repeat paracentesis (TTRP)
研究概览
简要总结
Assessment of effectiveness, safety and local immune activation of Oncolytic Viruses H101 in patients with refractory malignant ascites.
详细描述
This study is to evaluate the effectiveness of local immune activation, and safety in patients with refractory malignant ascites after Intraperitoneal injection of oncolytic Viruses H101.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent obtained.
- •Age ≥ 18 years at time of study entry.
- •Histologically diagnosed solid tumor malignancy.
- •Malignant peritoneal ascites confirmed by cytologic examination.
- •Failures from chemotherapy or other anti-cancer therapy or standard chemotherapy was no longer feasible.
- •Cooperative Oncology Group-Status (ECOG Status) ≤
- •life expectancy >8 weeks
- •Estimated ascites volume >1 L by CT scan.
- •At least one symptomatic paracentesis within 4 weeks as well as an objectively verified, clinical need for a second paracentesis
- •Adequate blood count, liver-enzymes, and renal function: absolute neutrophil count ≥ 1,500/uL, platelets ≥60 x103u/L; Total bilirubin ≤ 3 x upper normal limit; Aspartate Aminotransferase (SGOT), Alanine aminotransferase (SGPT) ≤ 5 x upper normal limit (ULN); International normalized ratio (INR) ≤1.25; Albumin ≥ 31 g/dL; Serum Creatinine ≤ 1.5 x institutional ULN or creatinine clearance (CrCl) ≥ 30 mL/min (if using the Cockcroft-Gault formula).
- •Female patients with reproductive potential must have a negative urine or serum pregnancy test within 7 days prior to start of trial.
- •Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment, adherence to contraceptive measures, scheduled visits and examinations including follow up.
排除标准
- •History or evidence of active autoimmune disease that requires systemic treatment.
- •Acute or chronic active Hepatitis B or C infection or HIV infection.
- •Previous (<4 weeks) or concurrent treatment with systemic or intraperitoneal chemotherapy or biological agents such as monoclonal antibodies.
- •Concurrent severe illness such as active infection.
- •Enteral feeding at study entry.
- •Ileus within the previous 30 days
- •>70% tumor infiltration of the liver or portal vein obstruction.
- •Arterial or venous thromboembolic disease.
- •Any condition or comorbidity that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results, including but not limited to:
- •Known acute or chronic pancreatitis
- •Active tuberculosis
- •Any other active infection (viral, fungal or bacterial) requiring systemic therapy
- •Has an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. Exceptions: Subjects with vitiligo, hypothyroidism, diabetes mellitus type I or resolved childhood asthma/atopy are an exception to this rule. Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Subjects with Hashimoto thyroiditis, hypothyroidism stable on hormone replacement or psoriasis not requiring treatment are not excluded from the study.
- •History or clinical evidence of Central Nervous System (CNS) metastases. Exceptions for subjects who have completed local therapy. Screening with CNS imaging (CT or MRI) is required only if clinically indicated or if the subject has a history of CNS.
- •Medication that is known to interfere with any of the agents applied in the trial.
- •Any other efficacious cancer treatment except protocol specified treatment at study start.
- •Patient has received any other investigational product within 28 days of study entry.
- •Female subjects who are pregnant, breast-feeding or male/female patients of reproductive potential who are not employing an effective method of birth control (failure rate of less than 1% per year).[Acceptable methods of contraception are implants, injectable contraceptives, combined oral contraceptives, intrauterine pessars (only hormonal devices), sexual abstinence or vasectomy of the partner]. Women of childbearing potential must have a negative pregnancy test (serum β-HCG) at screening.
- •Female subjects who are pregnant, breast-feeding or male/female patients of reproductive potential who are not employing an effective method of birth control (failure rate of less than 1% per year).[Acceptable methods of contraception are implants, injectable contraceptives, combine d oral contraceptives, intrauterine pessars (only hormonal devices), sexual abstinence or vasectomy of the partner]. Women of childbearing potential must have a negative pregnancy test (serum β-HCG) at screening.
- •Patient with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent.
研究组 & 干预措施
Oncorine (H101)
Experimental
H101 diluted in 5ml 0.9% sodium chloride solution will be intraperitoneally injected through the drainage catheter. Each patient will receive a dose of 1.5×10^12 vp by i.p. administration on day 1 and 3.
干预措施: Oncorine (H101) (Drug)
结局指标
主要结局
Time to repeat paracentesis (TTRP)
时间窗: max 6 months
Defined as the number of days between the first paracentesis (baseline) and the subsequent repeat paracentesis.
次要结局
- Paracentesis free survival (PaFS)(max 6 months)
- Analysis of adverse events(max 6 months)
- 60-day frequency of paracentesis(max 6 months)
- Overall survival (OS)(max 6 months)
- Change from baseline local and systemic immune effects after H101 intraperitoneal injections(at baseline, 3-, 7, 14 days after injection)
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
OH2 Oncolytic Viral Therapy in Advanced Bladder CancerAdvanced Bladder CarcinomaNCT05248789Binhui Biopharmaceutical Co., Ltd.4
进行中（未招募）
2 期
Intra-tumor Injection of Oncolytic Viruses H101 Combined With or Without Radiotherapy in Refractory/Recurrent Gynecological MalignanciesGenital Neoplasms, FemaleNCT05051696Liu Zi120
招募中
1 期
OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder CancerNon-muscle-invasive Bladder CancerNCT05232136Binhui Biopharmaceutical Co., Ltd.30
招募中
1 期
Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck CancerNCT06736379VLP Therapeutics41
已完成
1 期
A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal CarcinomatosisPeritoneal CarcinomatosisNCT01443260Genelux GmbH9